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Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming a world-wide public health problem. NAFLD represents a spectrum
of disease ranging from “simple steatosis”, which is considered relatively benign, to nonalcoholic steatohepatitis and to NAFLD-
associated cirrhosis and end-stage liver disease. The etiology of NAFLD and its progression is complex and remains incompletely
understood. The progression of the disease involves many factors. Apart from the two hits, the accumulation of TG and the
development of ﬁbrosis and necroinﬂammatory processes, exit numerous molecules associated with these two hits. Among them
we can highlight the pro-inﬂammatory molecules and adiponectins. This review focuses on the growing evidence from both
experimental and human studies suggesting a central role of cytokines in the pathogenesis of NAFLD. We review the role of
cytokines as key regulators of insulin sensitivity and hepatic lipid overloading, liver injury and inﬂammation, and ﬁbrosis with an
emphasis on potential therapeutic implications.
1.Introduction
Nonalcoholic fatty liver disease (NAFLD) is a chronic
inﬂammatory disease involving a wide range of disorders:
from simple steatosis; through steatohepatitis, ﬁbrosis and
cirrhosis;tohepatocarcinoma.Historically,steatosishasbeen
considered a benign disease. However, it is a necessary
requirement for the development of NAFLD, characterized
by the accumulation of lipids in the cytoplasm of hepato-
cytes. Its prevalence is not well known, but it is estimated
to be higher than 3%. It is a complex disease in which many
factors play a role including obesity, insulin resistance, and
oxidative stress, among others.
Nonalcoholicfattyliverdisease(NAFLD)ischaracterized
by liver damage similar to that caused by alcohol, but which
occurs in individuals that do not consume toxic quantities of
alcohol [1–10]. The prevalence of NAFLD is not well known,
but according to various studies, ranges between 3% and
24% [11–17]. It is likely that its prevalence will increase in
the future, due to an increase in the prevalence of being
overweight and obesity [18–21].
2.Etiology
NAFLD has been associated with many etiological factors [1,
2, 22], the most common ones being obesity, type 2 diabetes
mellitus, and dyslipidemia. In most series, one, two, or three
factorsoccurin80%and95%ofindividuals.Theassociation
between diabetes or intolerance to glucose and two or
more of the following clinical signs: obesity, hyperlipidemia,
high blood pressure, and hypoalbuminemia is known as
metabolic syndrome X [18, 21, 23]. This syndrome is also
associated with NAFLD.
Obesity (>10% of normal weight or Body Mass Index
>30) (BMI) is the most common cause of NAFLD: approx-
imately 80% of patients are obese, and the opposite is also
true, 80% obese people suﬀer from NAFLD [24–27].
Obesity and being overweight are problems of growing
importance in developed societies due to their prevalence,
not only in adults but also in children [28, 29]. They cause
several metabolic and associated disorders, such as resistance
to insulin, diabetes, and dyslipidemia [30]. Obesity is also
known to be a risk factor for chronic diseases such as:2 Mediators of Inﬂammation
diabetes, high blood pressure, heart and cerebrovascular
diseases, and some types of cancer [31–33].
3. Pathogenesis
The exact pathogenic mechanisms involved are still not well
known. However, available evidence has enabled a tenable
theory of pathogenesis to be proposed involving two stages,
known as “two-hit theory” [4, 34–37].
3.1. Two Hits Theory. The ﬁrst hit of steatosis, giving rise to
theﬁrstlesionsiscausedbyexcessfreefattyacids(FFA)inthe
liver, which are steriﬁed to triglycerides (TG) [38, 39]. These
initial lesions make the liver vulnerable to aggressive factors
of the second hit, which is caused by the oxidative stress and
proinﬂammatory cytokines (TNF-α, TGF-beta, IL-6, IL-8).
This leads to the occurrence of lesions in the hepatocytes,
inﬂammationandﬁbrosis,andconsequentlytheevolutionof
hepatic steatosis to steatohepatitits. Some poorly understood
genetic factors may explain whether steatosis evolves to
steatohepatitis or not [16, 34, 36, 37, 39–41].
3.1.1. First Hit. A feature of obesity, type 2 diabetes,
hyperlipidemia and metabolic syndrome X is resistance
to insulin [36, 42–44]. Adipocyte insensitivity to insulin
inhibits the regulation of the lipase in the adipose tissue,
and large quantities of free fatty acids (FFAs) are released
[41, 45–48]. Oversupply of FFAs to the liver is the main
mechanism that leads to steatosis in these patients. However
there are also other mechanisms. One of these is an increase
of insulinemia, whether or not caused by insulin resistance,
which inhibits the carnitine palmitoyltransferase enzyme,
and this reduces the mytochondria beta-oxidation of FFAs
[5, 49–51]. Hyperinsulinism also decreases the synthesis of
apolipoprotein B-100 in the liver, which causes a decrease in
the secretion of very low density lipoproteins (VLDL) [52,
53].Finally,excessproductionofexogenousandendogenous
glucose (in obesity and diabetes respectively), together with
hyperinsulinemia, increase the synthesis of FFAs in the liver.
T h eﬁ n a lr e s u l ti sap o s i t i v eF F Ab a l a n c e ,f r o mo v e r s u p p l y
and/or failure in lipid, leading to accumulation in the liver. It
is not well understood why not all patients with risk factors
(obesity, type 2 diabetes mellitus, hyperlipidemia) develop
NAFLD. Recently, it has been demonstrated that patients
with NAFLD have an increased prevalence of polymorphism
in TNF-α 238 (TNFA allele), inducing an overexpression
of TNF-α in adipose tissue, and this, in turn, disrupts
insulin receptors, causing resistance to insulin [53–55]. The
transcription factor HNF3α (hepatocyte nuclear factor) is
an important target for research. Its presence is related
to the inhibition of the accumulation of fatty acids. If
overexpressed, this transcription factor triggers a reduction
in the synthesis of fatty acids; that is, it has an opposite eﬀect
to steatosis [56–58].
3.1.2. Second Hit. FFAs cause an increase in the expression
of cytochrome P-450 2E1 (CYP 2E1). This is a microsomal
enzyme that takes part in the beta-oxidation of long and
very long chain FFAs, causing the production of reactive
oxygen metabolites [59]. On the other hand, some long-
chain FFAs are metabolized by peroxisomal beta-oxidation.
This oxidation generates hydrogen peroxide, that produces
hydroxyl radicals in the presence of iron, both being also
reactive oxygen metabolites [60]. The excess of reactive
oxygen metabolites depletes natural antioxidants such as
glutathione and vitamin E in the liver, causing oxidative
stressresultingin lipid peroxidation [26,35,39].Inturn,this
causes damage in the hepatocyte organelles and membranes,
leadingtodegenerationandhepatocellularnecrosis[26].The
damage caused by lipid peroxidation in mitochondria, apart
from changing their morphology (megamitochondria), dis-
tortsthetransferofelectronsintherespiratorychainandthis
results in more production of reactive oxygen metabolites,
closing the cycle by causing more oxidative stress [7, 16, 61–
63].
Oxidative stress activates the Fas ligand and nuclear fac-
tor kappa β (NF-kappa β). The former causes degeneration
and hepatocyte death, and the latter stimulates the synthesis
of proinﬂammatory cytokines (TNF-α,T G F - β,I L - 8 )[ 22]. In
addition,theﬁnalproductsoflipidperoxidation,malonalde-
hyde and 4-hydroxynonenal have chemotactic properties,
activating proinﬂammatory cytokines (TNF-α,T G F - β,I L -
6, IL-8) and stimulating hepatic collagen-producing stellate
cells. The end result is a mixed lesion, known as steato-
hepatitis, characterized by degeneration and hepatocyte
necrosis, inﬂammatory inﬁltrate and ﬁbrosis, as well as
steatosis [1, 22]. Malonaldehyde and 4-hydroxynonenal are
also covalently bound to proteins and produce protein
clusters with antigenic properties. Secondarily, antibodies
may appear, which are able to cause immune-mediated
hepatocellular injury (autoimmune hepatitis) [64]. One of
these protein inclusions corresponds to Mallory’s hyaline
[64]. Ongoing oxidative stress and lipid peroxidation results
in the continued production of collagen leading to ﬁbrosis
reaching the stage of hepatic cirrhosis [1, 36].
The passage of endotoxins from the intestine to the
splenic circulation causes portal endotoxemia. Endotoxins
stimulate the synthesis of proinﬂammatory cytokines in
the liver [36]. This mechanism is essential in the devel-
opment of steatohepatitis associated with intestinal bypass,
since this type of surgery encourages bacterial overgrowth
and endotoxemia from the dysfunctionalised loop [36].
Obese patients have intense intrahepatic expression of the
enzyme nitric oxide synthase [26], which is induced by
endotoxins and TNF-α;f u r t h e r m o r e ,o b e s em i c eh a v eb e e n
found to suﬀer from hepatic hypersensitivity which causes
them to develop more severe degrees of steatohepatitis
[4].
In this complex context, the role of several molecules are
involved.
Leptin. Leptin is an adipocyte-secreted, negative feedback
hormone that acts on the hypothalamus to regulate both
food intake and energy expenditure [65–67]. Leptin levels
are elevated in obesity [68]. It is believed that leptin has a
lipostatic function: when the quantity of fat stored in the
adipocytes increases, leptin is released into the bloodstream.Mediators of Inﬂammation 3
This constitutes a negative feedback signal to the hypothala-
mus, informing the hippocampus that the body has enough
food and the appetite should be reduced. When the adipose
tissue mass increases a certain level beyond equilibrium,
there is an increase of the synthesis and secretion of leptin,
triggering several compensating eﬀects in the hypothalamus:
a decrease in appetite by the production of anorexigenic
peptides (inducing loss of appetite) and the suppression of
orexigenic peptides; an increase in energy expenditure by
increasing of the basal metabolism and body temperature;
and also a change in the equilibrium levels of hormones
to reduce lipogenesis (production of fats) and to increase
lipolisis (use of the body fat stored to produce energy) in
the adipose tissue. The regulation of the secretion of leptin
takes place on long timescales, mainly due to variations in
body mass and stimulating eﬀects of insulin. Note however
that many obese people have high concentrations of leptin
in serum, or resistance to leptin, suggesting that other
molecules such as ghrelin, serotonin, cholecystokinin, and
the neuropeptide Y also have an eﬀect in the sensation of
satiety and contribute to body mass regulation. Speciﬁcally,
the secretion of leptin is correlated to body mass. It prevents
the occurrence of NAFLD, indirectly though the central
neuralpathway,anddirectlythroughtheactivationofAMPK
(AMP-activated protein kinase) [69–72]. Indeed, in patients
with NAFLD it has been observed that leptin levels are
directly correlated to the severity of the disease.
Leptin deﬁcient ob/ob mice show markedly reduced
levels of energy expedenditure and become obese even
when pair fed compared with littermate controls. The
marked steatosis observed in this group indicates that leptin
prevents fatty liver, both indirectly, through central neural
pathways, and directly via hepatic activation of adenosine
monophosphate-activated protein kinase (AMPK) [69–71].
In patients with NAFLD, the analysis of circulating levels
of leptin, has provided results more conﬂicting. Leptin
levels found to be increased in nonalcoholic steatohepatitis,
independentlyofBMI,withhigherinpatientswithadvanced
disease [73]. In an other study, leptin levels directly corre-
lated with the severity of steatosis but not with inﬂammation
or ﬁbrosis [74]. The strong evidence for leptin as a ﬁbrogenic
agent in animal models is not clearly paralleled by evidence
on circulating levels in patients [71].
Adiponectin. (Also known as Acrp30, AdipoQ, apM1 o
GBP28), a hormone synthesized exclusively by the adi-
pose tissue takes part in the metabolism of glucose and
fatty acids. It is secreted by adipocytes and is consid-
ered as an anti-inﬂammatory adipokine [68]. In general,
adiponectin reduces inﬂammation, stimulating secretion
of anti-inﬂammatory cytokines (e.g., IL-10), blocking NF-
KB activation, and inhibiting realease of TNF-α,I L - 6a n d
chemokines [75]. Adiponectin concentrations inversely cor-
related with fat mass and are down-regulated in obesity and
type 2 diabetes. Adiponectin exerts insulin-sensitizing eﬀects
in the liver, skeletal muscle, and adipose tissue. Like leptin,
adiponectin regulates whole-body lipid partitioning and has
hepatoprotective and antiﬁbrogenic eﬀect in condition of
liver injury [68].
In experimental alcoholic and nonalcoholic models, the
administration of adiponectin, ameliorated necroinﬂamma-
tion, and steatosis, partly via inhibition of TNF-α [76]. In
obesemice,theadministrationofadiponectinimprovedliver
injury, increasing PPAR- α and reducing TNF-α [77].
In patients with nonalcoholic steatohepatitis, adiponect-
in levels were reduced in comparison with control and
simple steatosis patients [78]. Bugianesi et al.[79] found that
adiponectin levels correlate with suppression of endogenous
glucoseproductionandpredictthepresenceofthemetabolic
syndrome. However, adiponectin levels was inversely associ-
ated only with intrahepatic fat but not with inﬂammation
and ﬁbrosis. In patients with diabetes, levels of adiponectin
are inversely correlated to hepatic fat content and to
endogenous glucose production. This hit suggests, that
adiponectin may represent a link between hepatic fat and
insulin resistance (IR) [80]. Also, gentic factors produce
alterations in the adiponectin levels. Polymorphisms of the
adiponectin gene have been associated with higher risk of
type 2 diabetes and cardiovascular disease [81].
Interleukin-6 (IL-6). It has a pleiotropic action, and in
animals models it has been associated with protection of
steatosis [71]. It is associated with hyperinsulinaemia and IR
[82].
IL-6 is overexpressed in the adipose tissue of obese
patiens [71]. Increased hepatic IL-6 production may play an
i m p o r t a n tr o l ei nN A S Hd e v e l o p m e n t ,a sw e l la si ns y s t e m i c
insulin resistance and diabetes [83]. Chronically elevated IL-
6 levels lead to inappropriate hyperinsulinaemia, reduced
body weight, impaired insulin-stimulated glucose uptake by
the skeletal muscles and marked inﬂammation in the liver.
Thus, the pleiotrophic eﬀects of chronically elevated IL-6
levels preclude any obvious usefulness in treating obesity or
its associated metabolic complications in man, despite the
fact that weight reduction may be expected [82].
Resistin. Resistin is a recently discovered adipokine, secreted
by adipose tissue and macrophages [68].
Several rodent models shown that resistin may be a link
betweenIRandobesity[70].Inresistin-deﬁcientmiceplaced
onhigh-fatdiet,fattyinﬁltrationandsecretionoflowdensity
lipoprotein are decreased. This suggests, a role of resistin in
the induction of hepatic steatosis [84].
In humans, the biology of resistin is not clearly deﬁned.
Most studies demonstrates that resistin is expressed by bone
marrow [72].
4.GeneticFactors
Not all patients with similar risk factors (obesity, diabetes,
hyperlipidemia, etc.) develop steatosis. Moreover, as with
alcoholic steatosis, not all the patients with simple steatosis
go on to develop the lesions characteristic of steatohepatitis
nor do all patients with steatohepatitis reach the stage of
cirrhosis, and those that do take widely varying times to
develop the condition. It has been suggested that this range
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factors, such as genetic polymorphism in the CYP2E1, TNF-
α, or IL-10 promoter regions [1]. In NAFLD, these genetic
factors are unknown but it has been suggested that the
development of steatosis may depend on the occurrence of
alterations in the genes involved in insulin resistance, or
in those codifying proteins that are involved in the hepatic
metabolism of lipids [85].
5. FutureTherapeutic Targets
The basic pillars to the treatment of NAFLD include weight
loss and change in lifestyle. Currently, are using diﬀerent
types of drugs for the treatment of non-alcoholic steatosis.
Among them we highlight the antidiabetic agents such
as pioglitazone, rosiglitazone, troglitazone, and metformin.
Rosiglitazone and troglitazone have been retired from the
m a r k e tb e c a u s ei tp r o d u c e ds e v e r el i v e rd a m a g e[ 86]. Met-
forministhemoleculebeingtestedtoday,asitcanreducethe
steatosis [87]. On the other hand, they have used drugs with
antioxidant powers as betaine, N-acetylcysteine, Vitamin E,
and other drugs, that apart from its antioxidant properties,
have cytoprotective properties, as ursodeoxycholic acid.
Finally,theyhavealsobeenusedasanticitoquinesdrugsanti-
TNF/Inﬂiximab [88].
All these studies are very preliminary. It is necessary
to test new drugs that have been able to stop steatosis.
Among the new drugs being tested, we emphasize the
Allopurinol [89], omega-3 fatty acids [90], bezaﬁbrate [91],
the combination of ezetimibe/simvastatin [92], SRT1720
(SIRT1activator)[93],Viusid(nutritionalsupplement)[94],
Pan-caspase [95], bicyclol [96] and Losartan [97]a m o n g
others. It has been observed that these drugs may be
promising, as they decrease injuries NAFLD. But remember
that these studies have been realized in animals and are
necessary human trials.
The above-mentioned molecules, represent a convincing
targetforthedevelopmentofnoveltherapiesinliverdiseases,
and adiponectins appear as the forerunner candidate.
Adiponectin concentrations are reduced in people suf-
fering from obesity, type 2 diabetes mellitus and coronary
arterial disease [71, 76, 98]. The proinﬂammatory cytokines
TNF-α and IL-6 play important roles in obesity and the
evolution of the disease [99–102]. Another target of interest
is the constitutive androstane receptor (CAR). It improves
the sensitivity to glucose and steatosis by inhibiting hepatic
lipogenesis and inducin β-oxidation [103]. Also, the peroxi-
some proliferator-activated receptor (PPARα) is responsible
for the increase in the oxidation of fatty acids and decreases
blood levels of triglycerides. In patients with steatosis, it
has been observed that its levels decrease considerably
[104], while those of the prolipogenic transcription factor
Sterol Regulatory Element Binding Proteins (SERBP-1c)
signiﬁcantly increase [105]. For these reasons, PPARα is also
considered to be an interesting target to study in relation to
lipid metabolism and obesity [104–106]
In the not too distant future, we must be able to
diagnose steatosis, without using invasive methods. Today,
for the diagnosis, liver biopsy is used, but it would be very
interesting to be able to perform diagnosis using noninvasive
techniques. For example, determining the amount of liver fat
by magnetic resonance techniques. It would be very useful to
perform a predictive test, but for this, we need much more
research about the interaction of diﬀerent factors, molecules,
and genes [107]. The identiﬁcation of the molecular mech-
anism leading to fat accumulation and oxidative imbalance
in steatotic livers, as well as genome and proteome studies
from patients to various stages of the disease, is expected
to improve the diagnostic and therapeutic approaches. In
this way, attractive pharmacological designs include new
molecules which can be able to decrease lipid from livers and
to improve insulin sensitivity.
The apparence of novel approaches is eagerly awaited.
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